Trial Profile
An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN: Once Long) [EXTENSION OF 700049241]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms BEGIN-ONCE-LONG
- Sponsors Novo Nordisk
- 19 Aug 2013 Results published in the Diabetic Medicine.
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 22 Jun 2013 Results presented at the 73rd Scientific Sessions of the American Diabetes Association (ADA), according to a Novo Nordisk media release.